📊 ACTU Key Takeaways
Is Actuate Therapeutics, Inc.. (ACTU) a Good Investment?
Actuate Therapeutics is a pre-revenue biotech company with severe operational losses (-$17.8M operating income) and negative free cash flow (-$15.5M), indicating no commercialized products generating revenue. Despite adequate liquidity (2.74x current ratio, $16.9M cash), the company is burning cash rapidly with only ~1 year of runway at current burn rates, creating acute financing risk absent near-term catalysts.
Actuate Therapeutics appears to be a pre-revenue biotech with no commercial income, persistent operating losses, and deeply negative returns on equity and assets, which makes current fundamental quality weak. The balance sheet is relatively clean with high cash balances, solid near-term liquidity, and no long-term debt, but cash burn of roughly $15.5M against $16.9M of cash suggests limited runway without meaningful clinical or financing progress.
Why Buy Actuate Therapeutics, Inc.. Stock? ACTU Key Strengths
- Strong liquidity position with $16.9M in cash and 2.74x current ratio providing near-term operational runway
- Zero debt obligations eliminating refinancing risk and balance sheet leverage concerns
- Lean asset base ($17.7M total assets) with modest liability burden ($6.8M), indicating no legacy encumbrances
- Strong liquidity with a 2.74x current and quick ratio
- Cash represents most of the asset base, supporting near-term operations
- No meaningful long-term debt, limiting balance-sheet leverage risk
ACTU Stock Risks: Actuate Therapeutics, Inc.. Investment Risks
- Pre-revenue stage with zero product commercialization and no revenue generation capability
- Severe cash burn of $15.5M annually with only ~1 year of financial runway remaining before depletion
- Negative profitability metrics across all dimensions (ROE -161.6%, ROA -99.8%, operating margin N/A) with no path to profitability visible
- Dilutive financing requirement imminent given runway constraints, likely destroying shareholder value
- No revenue base, so the business is not yet self-sustaining
- Large recurring losses and negative operating cash flow indicate heavy cash burn
- Likely need for future capital raises if burn remains near current levels
Key Metrics to Watch
- Cash burn rate and remaining cash runway duration (critical survival metric)
- Clinical trial progress and regulatory milestones for any lead candidates
- Operating expense trends and evidence of cost efficiency improvements
- Quarterly operating cash burn relative to cash on hand
- Clinical and regulatory progress that could translate into revenue or partnership inflows
Actuate Therapeutics, Inc.. (ACTU) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.74x current ratio provides a solid financial cushion.
ACTU Profit Margin, ROE & Profitability Analysis
ACTU vs Healthcare Sector: How Actuate Therapeutics, Inc.. Compares
How Actuate Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Actuate Therapeutics, Inc.. Stock Overvalued? ACTU Valuation Analysis 2026
Based on fundamental analysis, Actuate Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Actuate Therapeutics, Inc.. Balance Sheet: ACTU Debt, Cash & Liquidity
ACTU Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Actuate Therapeutics, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.26 indicates the company is currently unprofitable.
ACTU Revenue Growth, EPS Growth & YoY Performance
Actuate Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
ACTU SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Actuate Therapeutics, Inc.. (CIK: 0001652935)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACTU
What is the AI rating for ACTU?
Actuate Therapeutics, Inc.. (ACTU) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 85% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACTU's key strengths?
Claude: Strong liquidity position with $16.9M in cash and 2.74x current ratio providing near-term operational runway. Zero debt obligations eliminating refinancing risk and balance sheet leverage concerns. ChatGPT: Strong liquidity with a 2.74x current and quick ratio. Cash represents most of the asset base, supporting near-term operations.
What are the risks of investing in ACTU?
Claude: Pre-revenue stage with zero product commercialization and no revenue generation capability. Severe cash burn of $15.5M annually with only ~1 year of financial runway remaining before depletion. ChatGPT: No revenue base, so the business is not yet self-sustaining. Large recurring losses and negative operating cash flow indicate heavy cash burn.
What is ACTU's revenue and growth?
Actuate Therapeutics, Inc.. reported revenue of N/A.
Does ACTU pay dividends?
Actuate Therapeutics, Inc.. does not currently pay dividends.
Where can I find ACTU SEC filings?
Official SEC filings for Actuate Therapeutics, Inc.. (CIK: 0001652935) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACTU's EPS?
Actuate Therapeutics, Inc.. has a diluted EPS of $-0.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACTU a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Actuate Therapeutics, Inc.. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACTU stock overvalued or undervalued?
Valuation metrics for ACTU: ROE of -161.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ACTU stock in 2026?
Our dual AI analysis gives Actuate Therapeutics, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACTU's free cash flow?
Actuate Therapeutics, Inc..'s operating cash flow is $-15.5M, with capital expenditures of N/A.
How does ACTU compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -161.6% (avg: 15%), current ratio 2.74 (avg: 2).